FMT Performance Prediction Test for GVHD Patient Selection

The patent applies preliminary action by performing microbiota assessment and predicting FMT response before administering the treatment. The method evaluates baseline microbiota composition and identifies patients likely to respond to FMT, allowing clinicians to select appropriate candidates in advance and avoid wasting resources on patients who would not benefit from the treatment.

The patent applies local quality by providing conditioning treatments selectively to specific patient subgroups based on their microbiota profile. Rather than treating all patients uniformly, the method identifies which patients have microbiota characteristics that would benefit from conditioning (such as those with severe dysbiosis or low baseline diversity) and applies conditioning only to them, while allowing patients with favorable baseline microbiota to proceed directly to FMT.

The patent applies segmentation by dividing the patient population into distinct groups based on their microbiota characteristics and predicted FMT response. The method segments patients into those likely to respond to FMT and those unlikely to respond, and further segments the responsive group into those who need conditioning and those who can proceed directly to FMT. This segmentation enables rapid decision-making and streamlined treatment pathways for each subgroup.